Table 2

Overall associations between NOS2A and new-onset asthma or FEV1 growth (in ml) assessed using haplotype-based analysis

NOS2A regionHaplotypeNew-onset asthma8-year growth in FEV1
HR (95% CI)†p Value§Estimate (95% CI)‡p Value§
Segment 1h0110010Ref.0.06Ref.0.46
(Blocks 1–3)h10000000.72 (0.51 to 1.01)9.57 (−31.99 to 51.14)
h10011011.30 (0.93 to 1.8)27.64 (−19.76 to 75.04)
h00000001.00 (0.71 to 1.42)12.40 (−34.78 to 59.57)
Other*0.92 (0.62 to 1.37)−25.24 (−75.13 to 24.65)
Segment 2h0101100010Ref.0.25Ref.0.71
(Blocks 4–6)h10101110011.21 (0.81 to 1.81)−6.64 (−61.13 to 47.84)
h00100001000.66 (0.41 to 1.05)31.86 (−21.68 to 85.40)
h00100001011.30 (0.84 to 2.03)−12.89 (−74.98 to 49.20)
h01010000100.79 (0.48 to 1.30)−32.94 (−92.81 to 26.92)
h00000001001.13 (0.73 to 1.74)−2.89 (−61.28 to 55.51)
h10010110011.07 (0.63 to 1.82)31.14 (−41.84 to 104.12)
h00010000010.99 (0.49 to 1.99)10.34 (−82.78 to 103.47)
Other*0.96 (0.64 to 1.45)1.07 (−55.16 to 57.30)
Block 7h0111101Ref.0.02Ref.0.10
h10000100.66 (0.49 to 0.88)48.90 (11.60 to 86.20)
h00000100.84 (0.60 to 1.18)3.86 (−41.95 to 49.68)
h00000000.62 (0.44 to 0.88)17.04 (−26.77 to 60.85)
Other*0.85 (0.42, 1.74)1.30 (−107.56 to 110.17)
  • * Haplotypes with <5% frequencies are grouped into the “Other” category.

  • HR and 95% CI are based on fitting the Cox proportional hazard model (for details see the Methods section).

  • Estimate and 95% CI are based on hierarchical mixed effects model (for details see the Methods section).

  • § p Values are based on a likelihood ratio test comparing models with and without genetic data.

  • FEV1, forced expiratory volume in 1 s.